Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report

Remap-Cap Investigators, AC Gordon, PR Mouncey… - MedRxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
被引用次数：1410 相关文章

[引用][C] Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

D Parekh - The New England Journal of Medicine, 2021 - research.birmingham.ac.uk
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 — University of
Birmingham Skip to main navigation Skip to search Skip to main content University of …
[HTML] medrxiv.org

[HTML][HTML] Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19–Preliminary report

AC Gordon, PR Mouncey, F Al-Beidh, KM Rowan… - medRxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

[引用][C] Interleukin-6 receptor antagonists in critically ill patients with Covid-19—preliminary report.

AC Gordon - medRxiv., 2021 - cir.nii.ac.jp
Interleukin-6 receptor antagonists in critically ill patients with Covid-19—preliminary report. |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19-Preliminary report

AC Gordon, REMAP-CAP Investigators - 2021 - pesquisa.bvsalud.org
BackgroundThe efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. MethodsWe evaluated tocilizumab and …

Interleukin-6 receptor antagonists in critically ill patients with covid-19

AC Gordon, PR Mouncey, F Al-Beidh… - New England Journal …, 2021 - hal.science
BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. METHODS We evaluated tocilizumab and …

Interleukin-6 receptor antagonists in critically ill patients with covid-19

AC Gordon, PR Mouncey, F Al-Beidh, KM Rowan… - 2021 - ses.library.usyd.edu.au
BACKGROUND: The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. METHODS We evaluated tocilizumab and …

[引用][C] Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

AC Gordon, F Al-Beidh, KM Rowan… - … England Journal of …, 2021 - researchportal.helsinki.fi
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 — University of
Helsinki Skip to main navigation Skip to search Skip to main content University of Helsinki …

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

AC Gordon, PR Mouncey, F Al‑Beidh… - New England Journal of …, 2021 - ora.ox.ac.uk
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

AC Gordon, PR Mouncey, F Al-Beidh, KM Rowan… - sussex.figshare.com
BACKGROUND The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. METHODS We evaluated tocilizumab and …